Difference between revisions of "Quizartinib (Vanflyta)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
FLT3 inhibitor | FLT3 inhibitor | ||
+ | |||
+ | ==Toxicity management== | ||
+ | *[https://vanflytarems.com/ Link to REMS program] | ||
==Diseases for which it is established== | ==Diseases for which it is established== | ||
Line 23: | Line 26: | ||
[[Category:PMDA approved in 2019]] | [[Category:PMDA approved in 2019]] | ||
[[Category:FDA approved in 2023]] | [[Category:FDA approved in 2023]] | ||
+ | [[Category:REMS program]] |
Revision as of 12:28, 18 August 2023
Mechanism of action
FLT3 inhibitor
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-07-20: Approved with standard cytarabine and anthracycline induction for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
- 2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
- 2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
History of changes in PMDA indication
- 2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.
Also known as
- Code names: AC-220, ASP-2689
- Brand name: Vanflyta